From locus to gene: causal inference and experimental validation prioritize PSMA4 as a candidate target in lung

Hui Lu1, Sai Wang1, Yuhang Ma1

  • 1Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China.

Insights

This study identifies PSMA4 as a key target in lung adenocarcinoma (LUAD) by integrating genetic and multi-omics data. PSMA4 knockdown inhibits LUAD progression, offering a potential new therapeutic strategy for this deadly cancer.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Lung adenocarcinoma (LUAD) causes significant cancer mortality globally.
  • Therapeutic resistance limits current targeted therapy and immunotherapy efficacy in LUAD.
  • Identifying novel, actionable targets is crucial for improving LUAD patient outcomes.

Purpose of the Study:

  • To prioritize candidate genes associated with LUAD risk using integrative genetic analyses.
  • To identify and validate novel therapeutic targets for lung adenocarcinoma.
  • To elucidate the functional role and mechanism of candidate genes in LUAD progression.

Main Methods:

  • Summary-data-based Mendelian randomization (SMR) integrated GWAS, cis-eQTL, and cis-mQTL data.
  • HEIDI and Bayesian colocalization analyses assessed SMR signal robustness.
  • Independent transcriptomic data, GEO datasets, PPI, and functional enrichment analyses validated candidate genes.

Main Results:

  • PSMA4 (Proteasome 20S Subunit Alpha 4) was prioritized as a leading LUAD-relevant gene.
  • PSMA4 overexpression correlated with adverse prognosis; knockdown suppressed LUAD cell proliferation, migration, invasion, and tumor growth.
  • PSMA4 facilitates p53 degradation via the proteasome, attenuating p53 signaling.

Conclusions:

  • PSMA4 is a biologically relevant and potentially actionable therapeutic target in lung adenocarcinoma.
  • PSMA4 promotes LUAD progression by destabilizing p53.
  • These findings provide a mechanistic basis for PSMA4-targeted translational research in LUAD.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...